Global Multiple Sclerosis (MS) Drugs Market Insights and Forecast to 2026

Global Multiple Sclerosis (MS) Drugs Market Insights and Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Multiple Sclerosis (MS) Drugs Product Introduction
1.2 Market Segments
1.3 Key Multiple Sclerosis (MS) Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Type
1.4.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.4.3 Novantrone (Mitoxantrone)
1.4.4 Gilenya (Fingolimod, Fty720)
1.4.5 Aubagio (Teriflunomide)
1.4.6 Tecfidera (Dimethyl Fumarate)
1.4.7 Firategrast (Sb683699, T-0047)
1.4.8 Siponimod (Baf312)
1.4.9 Others
1.5 Market by Application
1.5.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Application
1.5.2 RRMS
1.5.3 SPMS
1.5.4 PPMS
1.5.5 PRMS
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Multiple Sclerosis (MS) Drugs Market Size, Estimates and Forecasts
2.1.1 Global Multiple Sclerosis (MS) Drugs Revenue 2015-2026
2.1.2 Global Multiple Sclerosis (MS) Drugs Sales 2015-2026
2.2 Global Multiple Sclerosis (MS) Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Multiple Sclerosis (MS) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Multiple Sclerosis (MS) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Multiple Sclerosis (MS) Drugs Competitor Landscape by Players
3.1 Multiple Sclerosis (MS) Drugs Sales by Manufacturers
3.1.1 Multiple Sclerosis (MS) Drugs Sales by Manufacturers (2015-2020)
3.1.2 Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Multiple Sclerosis (MS) Drugs Revenue by Manufacturers
3.2.1 Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Multiple Sclerosis (MS) Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Multiple Sclerosis (MS) Drugs Revenue in 2019
3.2.5 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Multiple Sclerosis (MS) Drugs Price by Manufacturers
3.4 Multiple Sclerosis (MS) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Multiple Sclerosis (MS) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Multiple Sclerosis (MS) Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Multiple Sclerosis (MS) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Multiple Sclerosis (MS) Drugs Market Size by Type (2015-2020)
4.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2015-2020)
4.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2015-2020)
4.1.3 Multiple Sclerosis (MS) Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Multiple Sclerosis (MS) Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Multiple Sclerosis (MS) Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Multiple Sclerosis (MS) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Multiple Sclerosis (MS) Drugs Market Size by Application (2015-2020)
5.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2015-2020)
5.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2015-2020)
5.1.3 Multiple Sclerosis (MS) Drugs Price by Application (2015-2020)
5.2 Multiple Sclerosis (MS) Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Multiple Sclerosis (MS) Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Multiple Sclerosis (MS) Drugs by Country
6.1.1 North America Multiple Sclerosis (MS) Drugs Sales by Country
6.1.2 North America Multiple Sclerosis (MS) Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
6.3 North America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Multiple Sclerosis (MS) Drugs by Country
7.1.1 Europe Multiple Sclerosis (MS) Drugs Sales by Country
7.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
7.3 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Multiple Sclerosis (MS) Drugs by Region
8.1.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Region
8.1.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
8.3 Asia Pacific Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Multiple Sclerosis (MS) Drugs by Country
9.1.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Country
9.1.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
9.3 Central & South America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Multiple Sclerosis (MS) Drugs by Country
10.1.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country
10.1.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Bayer AG
11.1.1 Bayer AG Corporation Information
11.1.2 Bayer AG Description and Business Overview
11.1.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Products Offered
11.1.5 Bayer AG Related Developments
11.2 Bayhill Therapeutics
11.2.1 Bayhill Therapeutics Corporation Information
11.2.2 Bayhill Therapeutics Description and Business Overview
11.2.3 Bayhill Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
11.2.5 Bayhill Therapeutics Related Developments
11.3 Biogen Idec
11.3.1 Biogen Idec Corporation Information
11.3.2 Biogen Idec Description and Business Overview
11.3.3 Biogen Idec Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Products Offered
11.3.5 Biogen Idec Related Developments
11.4 Cinnagen
11.4.1 Cinnagen Corporation Information
11.4.2 Cinnagen Description and Business Overview
11.4.3 Cinnagen Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Products Offered
11.4.5 Cinnagen Related Developments
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Corporation Information
11.5.2 Daiichi Sankyo Description and Business Overview
11.5.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Products Offered
11.5.5 Daiichi Sankyo Related Developments
11.6 Eli Lilly
11.6.1 Eli Lilly Corporation Information
11.6.2 Eli Lilly Description and Business Overview
11.6.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Products Offered
11.6.5 Eli Lilly Related Developments
11.7 Fast Forward Llc
11.7.1 Fast Forward Llc Corporation Information
11.7.2 Fast Forward Llc Description and Business Overview
11.7.3 Fast Forward Llc Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Products Offered
11.7.5 Fast Forward Llc Related Developments
11.8 Antisense Therapeutics
11.8.1 Antisense Therapeutics Corporation Information
11.8.2 Antisense Therapeutics Description and Business Overview
11.8.3 Antisense Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
11.8.5 Antisense Therapeutics Related Developments
11.9 Apitope
11.9.1 Apitope Corporation Information
11.9.2 Apitope Description and Business Overview
11.9.3 Apitope Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Apitope Multiple Sclerosis (MS) Drugs Products Offered
11.9.5 Apitope Related Developments
11.10 Five Prime Therapeutics
11.10.1 Five Prime Therapeutics Corporation Information
11.10.2 Five Prime Therapeutics Description and Business Overview
11.10.3 Five Prime Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
11.10.5 Five Prime Therapeutics Related Developments
11.1 Bayer AG
11.1.1 Bayer AG Corporation Information
11.1.2 Bayer AG Description and Business Overview
11.1.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Products Offered
11.1.5 Bayer AG Related Developments
11.12 Artielle Immunotherapeutics
11.12.1 Artielle Immunotherapeutics Corporation Information
11.12.2 Artielle Immunotherapeutics Description and Business Overview
11.12.3 Artielle Immunotherapeutics Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Artielle Immunotherapeutics Products Offered
11.12.5 Artielle Immunotherapeutics Related Developments
11.13 Genzyme
11.13.1 Genzyme Corporation Information
11.13.2 Genzyme Description and Business Overview
11.13.3 Genzyme Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Genzyme Products Offered
11.13.5 Genzyme Related Developments
11.14 Glaxosmithkline
11.14.1 Glaxosmithkline Corporation Information
11.14.2 Glaxosmithkline Description and Business Overview
11.14.3 Glaxosmithkline Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Glaxosmithkline Products Offered
11.14.5 Glaxosmithkline Related Developments
11.15 Gw Pharmaceuticals
11.15.1 Gw Pharmaceuticals Corporation Information
11.15.2 Gw Pharmaceuticals Description and Business Overview
11.15.3 Gw Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Gw Pharmaceuticals Products Offered
11.15.5 Gw Pharmaceuticals Related Developments
11.16 Innate Immunotherapeutics
11.16.1 Innate Immunotherapeutics Corporation Information
11.16.2 Innate Immunotherapeutics Description and Business Overview
11.16.3 Innate Immunotherapeutics Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Innate Immunotherapeutics Products Offered
11.16.5 Innate Immunotherapeutics Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Multiple Sclerosis (MS) Drugs Market Estimates and Projections by Region
12.1.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
12.2.2 North America: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Multiple Sclerosis (MS) Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Multiple Sclerosis (MS) Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Multiple Sclerosis (MS) Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Multiple Sclerosis (MS) Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Multiple Sclerosis (MS) Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Multiple Sclerosis (MS) Drugs Market Segments
Table 2. Ranking of Global Top Multiple Sclerosis (MS) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Copaxone (Glatiramer Acetate, Copolymer 1)
Table 5. Major Manufacturers of Novantrone (Mitoxantrone)
Table 6. Major Manufacturers of Gilenya (Fingolimod, Fty720)
Table 7. Major Manufacturers of Aubagio (Teriflunomide)
Table 8. Major Manufacturers of Tecfidera (Dimethyl Fumarate)
Table 9. Major Manufacturers of Firategrast (Sb683699, T-0047)
Table 10. Major Manufacturers of Siponimod (Baf312)
Table 11. Major Manufacturers of Others
Table 12. Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 13. Global Multiple Sclerosis (MS) Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 14. Global Multiple Sclerosis (MS) Drugs Sales by Regions 2015-2020 (K Pcs)
Table 15. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Regions (2015-2020)
Table 16. Global Multiple Sclerosis (MS) Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 18. Global Multiple Sclerosis (MS) Drugs Sales Share by Manufacturers (2015-2020)
Table 19. Global Multiple Sclerosis (MS) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Multiple Sclerosis (MS) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Sclerosis (MS) Drugs as of 2019)
Table 21. Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Multiple Sclerosis (MS) Drugs Price (2015-2020) (USD/Pcs)
Table 24. Multiple Sclerosis (MS) Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Multiple Sclerosis (MS) Drugs Product Type
Table 26. Date of International Manufacturers Enter into Multiple Sclerosis (MS) Drugs Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Multiple Sclerosis (MS) Drugs Sales by Type (2015-2020) (K Pcs)
Table 29. Global Multiple Sclerosis (MS) Drugs Sales Share by Type (2015-2020)
Table 30. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Multiple Sclerosis (MS) Drugs Revenue Share by Type (2015-2020)
Table 32. Multiple Sclerosis (MS) Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 33. Global Multiple Sclerosis (MS) Drugs Sales by Application (2015-2020) (K Pcs)
Table 34. Global Multiple Sclerosis (MS) Drugs Sales Share by Application (2015-2020)
Table 35. North America Multiple Sclerosis (MS) Drugs Sales by Country (2015-2020) (K Pcs)
Table 36. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2015-2020)
Table 37. North America Multiple Sclerosis (MS) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2015-2020)
Table 39. North America Multiple Sclerosis (MS) Drugs Sales by Type (2015-2020) (K Pcs)
Table 40. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 41. North America Multiple Sclerosis (MS) Drugs Sales by Application (2015-2020) (K Pcs)
Table 42. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 43. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2015-2020) (K Pcs)
Table 44. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2015-2020)
Table 45. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2015-2020)
Table 47. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2015-2020) (K Pcs)
Table 48. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 49. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2015-2020) (K Pcs)
Table 50. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2015-2020) (K Pcs)
Table 52. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Type (2015-2020) (K Pcs)
Table 56. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Application (2015-2020) (K Pcs)
Table 58. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 59. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2015-2020) (K Pcs)
Table 60. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Multiple Sclerosis (MS) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2015-2020)
Table 63. Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2015-2020) (K Pcs)
Table 64. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 65. Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2015-2020) (K Pcs)
Table 66. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2015-2020) (K Pcs)
Table 68. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Type (2015-2020) (K Pcs)
Table 72. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Application (2015-2020) (K Pcs)
Table 74. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 75. Bayer AG Corporation Information
Table 76. Bayer AG Description and Major Businesses
Table 77. Bayer AG Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Bayer AG Product
Table 79. Bayer AG Recent Development
Table 80. Bayhill Therapeutics Corporation Information
Table 81. Bayhill Therapeutics Description and Major Businesses
Table 82. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Bayhill Therapeutics Product
Table 84. Bayhill Therapeutics Recent Development
Table 85. Biogen Idec Corporation Information
Table 86. Biogen Idec Description and Major Businesses
Table 87. Biogen Idec Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Biogen Idec Product
Table 89. Biogen Idec Recent Development
Table 90. Cinnagen Corporation Information
Table 91. Cinnagen Description and Major Businesses
Table 92. Cinnagen Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Cinnagen Product
Table 94. Cinnagen Recent Development
Table 95. Daiichi Sankyo Corporation Information
Table 96. Daiichi Sankyo Description and Major Businesses
Table 97. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Daiichi Sankyo Product
Table 99. Daiichi Sankyo Recent Development
Table 100. Eli Lilly Corporation Information
Table 101. Eli Lilly Description and Major Businesses
Table 102. Eli Lilly Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Eli Lilly Product
Table 104. Eli Lilly Recent Development
Table 105. Fast Forward Llc Corporation Information
Table 106. Fast Forward Llc Description and Major Businesses
Table 107. Fast Forward Llc Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Fast Forward Llc Product
Table 109. Fast Forward Llc Recent Development
Table 110. Antisense Therapeutics Corporation Information
Table 111. Antisense Therapeutics Description and Major Businesses
Table 112. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 113. Antisense Therapeutics Product
Table 114. Antisense Therapeutics Recent Development
Table 115. Apitope Corporation Information
Table 116. Apitope Description and Major Businesses
Table 117. Apitope Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 118. Apitope Product
Table 119. Apitope Recent Development
Table 120. Five Prime Therapeutics Corporation Information
Table 121. Five Prime Therapeutics Description and Major Businesses
Table 122. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Five Prime Therapeutics Product
Table 124. Five Prime Therapeutics Recent Development
Table 125. Genmab Corporation Information
Table 126. Genmab Description and Major Businesses
Table 127. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Genmab Product
Table 129. Genmab Recent Development
Table 130. Artielle Immunotherapeutics Corporation Information
Table 131. Artielle Immunotherapeutics Description and Major Businesses
Table 132. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Artielle Immunotherapeutics Product
Table 134. Artielle Immunotherapeutics Recent Development
Table 135. Genzyme Corporation Information
Table 136. Genzyme Description and Major Businesses
Table 137. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Genzyme Product
Table 139. Genzyme Recent Development
Table 140. Glaxosmithkline Corporation Information
Table 141. Glaxosmithkline Description and Major Businesses
Table 142. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Glaxosmithkline Product
Table 144. Glaxosmithkline Recent Development
Table 145. Gw Pharmaceuticals Corporation Information
Table 146. Gw Pharmaceuticals Description and Major Businesses
Table 147. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 148. Gw Pharmaceuticals Product
Table 149. Gw Pharmaceuticals Recent Development
Table 150. Innate Immunotherapeutics Corporation Information
Table 151. Innate Immunotherapeutics Description and Major Businesses
Table 152. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 153. Innate Immunotherapeutics Product
Table 154. Innate Immunotherapeutics Recent Development
Table 155. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 156. Global Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 157. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 158. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 159. North America: Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 160. North America: Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 161. Europe: Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 162. Europe: Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 163. Asia Pacific: Multiple Sclerosis (MS) Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 164. Asia Pacific: Multiple Sclerosis (MS) Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 165. Latin America: Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 166. Latin America: Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 167. Middle East and Africa: Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 168. Middle East and Africa: Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 169. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 170. Key Challenges
Table 171. Market Risks
Table 172. Main Points Interviewed from Key Multiple Sclerosis (MS) Drugs Players
Table 173. Multiple Sclerosis (MS) Drugs Customers List
Table 174. Multiple Sclerosis (MS) Drugs Distributors List
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Multiple Sclerosis (MS) Drugs Product Picture
Figure 2. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Copaxone (Glatiramer Acetate, Copolymer 1) Product Picture
Figure 4. Novantrone (Mitoxantrone) Product Picture
Figure 5. Gilenya (Fingolimod, Fty720) Product Picture
Figure 6. Aubagio (Teriflunomide) Product Picture
Figure 7. Tecfidera (Dimethyl Fumarate) Product Picture
Figure 8. Firategrast (Sb683699, T-0047) Product Picture
Figure 9. Siponimod (Baf312) Product Picture
Figure 10. Others Product Picture
Figure 11. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2020 & 2026
Figure 12. RRMS
Figure 13. SPMS
Figure 14. PPMS
Figure 15. PRMS
Figure 16. Multiple Sclerosis (MS) Drugs Report Years Considered
Figure 17. Global Multiple Sclerosis (MS) Drugs Market Size 2015-2026 (US$ Million)
Figure 18. Global Multiple Sclerosis (MS) Drugs Sales 2015-2026 (K Pcs)
Figure 19. Global Multiple Sclerosis (MS) Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 20. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2015-2020)
Figure 21. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region in 2019
Figure 22. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2015-2020)
Figure 23. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region in 2019
Figure 24. Global Multiple Sclerosis (MS) Drugs Sales Share by Manufacturer in 2019
Figure 25. The Top 10 and 5 Players Market Share by Multiple Sclerosis (MS) Drugs Revenue in 2019
Figure 26. Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 27. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Figure 28. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2019
Figure 29. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2015-2020)
Figure 30. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type in 2019
Figure 31. Global Multiple Sclerosis (MS) Drugs Market Share by Price Range (2015-2020)
Figure 32. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Figure 33. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2019
Figure 34. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2015-2020)
Figure 35. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application in 2019
Figure 36. North America Multiple Sclerosis (MS) Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 37. North America Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 38. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2019
Figure 39. North America Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2019
Figure 40. U.S. Multiple Sclerosis (MS) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 41. U.S. Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. Canada Multiple Sclerosis (MS) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 43. Canada Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. North America Multiple Sclerosis (MS) Drugs Market Share by Type in 2019
Figure 45. North America Multiple Sclerosis (MS) Drugs Market Share by Application in 2019
Figure 46. Europe Multiple Sclerosis (MS) Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 47. Europe Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 48. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2019
Figure 49. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2019
Figure 50. Germany Multiple Sclerosis (MS) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. Germany Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. France Multiple Sclerosis (MS) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. France Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. U.K. Multiple Sclerosis (MS) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. U.K. Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Italy Multiple Sclerosis (MS) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. Italy Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Russia Multiple Sclerosis (MS) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 59. Russia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Europe Multiple Sclerosis (MS)

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs